Ambrx Biopharma Inc. American Depositary Shares (AMAM) Stock
AMAM is no longer traded. Ambrx Biopharma Inc. American Depositary Shares was acquired by Johnson & Johnson (JNJ) on March 7, 2024.
Each AMAM share was exchanged for $28.00 per American Depositary Share in cash. Prices on this page are historical; the last trade was March 6, 2024 at $28.00.
See Johnson & Johnson (JNJ) stock →Ambrx Biopharma Inc. American Depositary Shares stock price history
AMAM final trading statistics
- Final close
- $28.00
- Final trading day
- Mar 6, 2024
- Market cap at delisting
- $1.77B
- Shares outstanding
- 63.29M
- Final 52-week range
- $6.55 – $28.15
- Avg. volume (final 3 mo.)
- 1,926,333
- All-time high (split-adj.)
- $28.09 · Jan 2024
- All-time low (split-adj.)
- $0.41 · Dec 2022
- Return since IPO
- +64.2%
- Beta
- -2.36
- Book value / share
- $3.85
- Price / book
- 7.28
Ambrx Biopharma Inc. American Depositary Shares annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $4.09M | -$67.1M | — |
| FY2022 | $7.40M | -$78.0M | -$1.68 |
| FY2021 | $7.46M | -$68.3M | — |
| FY2020 | $13.67M | -$17.8M | -$5.86 |
| FY2019 | $10.31M | -$22.3M | -$0.14 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Ambrx Biopharma Inc. American Depositary Shares
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California. As of March 7, 2024, Ambrx Biopharma Inc. operates as a subsidiary of Johnson & Johnson.
Ambrx Biopharma Inc. American Depositary Shares stock FAQ
What happened to Ambrx Biopharma Inc. American Depositary Shares stock?
Ambrx Biopharma Inc. American Depositary Shares was acquired by Johnson & Johnson (JNJ) on March 7, 2024. Shareholders received $28.00 per American Depositary Share in cash for each share. AMAM stock stopped trading on the Nasdaq, with a final close of $28.00 on March 6, 2024.
What did Ambrx Biopharma Inc. American Depositary Shares shareholders receive?
Each AMAM share was converted into $28.00 per American Depositary Share in cash. The deal was valued at about $2 billion.
Is AMAM stock still trading?
No. AMAM was delisted from the Nasdaq on March 7, 2024 and no longer trades on a U.S. exchange. Former Ambrx Biopharma Inc. American Depositary Shares shareholders received Johnson & Johnson (JNJ) shares.
What was the last price of AMAM stock?
AMAM closed at $28.00 on its final trading day, March 6, 2024, for a market value of about $1.77B.
What were Ambrx Biopharma Inc. American Depositary Shares's revenue and earnings in its last full fiscal year?
Ambrx Biopharma Inc. American Depositary Shares reported revenue of $4.09M and net income of -$67.1M in fiscal 2023, its last full year as a public company.
When did Ambrx Biopharma Inc. American Depositary Shares go public?
Ambrx Biopharma Inc. American Depositary Shares stock began trading on June 18, 2021.